Tezepelumab Deemed Breakthrough But Can Phase III Reproduce Data?
Executive Summary
Biologic's breakthrough designation is based on Phase IIb PATHWAY data that showed tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma.
You may also be interested in...
Interview: AstraZeneca ‘Is More Than Oncology’
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”
AZ Heads Talk Pipeline And Partnerships
The drugs major believes it has assembled a pipeline that is looking well stocked for several years to come.
Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports